1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

11 Mar 2024
Admin
News Article

K MHRA Grants Marketing Approval for Ganaxolone

K MHRA grants marketing approval for Marinus Pharma’s ganaxolone to treat rare epileptic seizure disorder

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has on 7th March, 2024 approved the medicine ganaxolone (Ztalmy) as the first anti-seizure medication in the UK to treat cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).

CDD: Epidemiology

CDD is a rare genetic disorder caused by mutations in the CDLK5 gene, which is necessary for normal brain development, and affects around 1 in 42,000 people in the UK.
Most people affected experience seizures from as early as the first week of life and have severe delays in development, impacting brain function, movement, speech and sight.
The new marketing authorisation was granted on 7th March, 2024 to Marinus Pharmaceuticals Emerald Limited.

Word from MHRA

Julian Beach, MHRA Interim executive director, healthcare quality and access, said: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.
We’re assured that the appropriate regulatory standards for the approval of this medicine have been met.
“As with all medicines, we will keep its safety under close review.”

Dosage

The treatment is taken orally through a dosing syringe.
The prescribing doctor or pharmacist will advise as to the number of doses each person should take.

About Ganaxolone

Ganaxolone is a steroid that attaches to specific receptors in the brain and aims to stop epileptic seizures.

Trial Behind Approval

This approval is supported by evidence from a phase 3 randomised, double-blind, placebo-controlled clinical trial involving 101 patients with CDD aged 2 to 19 years.
Chosen at random, 51 patients were given the placebo and the other 50 received ganaxolone for 17 weeks.
After 13 weeks, there was a statistically significant difference in 28-day seizure frequency between the two groups.
Patients receiving ganaxolone saw an average reduction in seizure frequency of almost 30%, while those receiving the placebo had a reduction of almost 6.5%.

Side Effects

The most common side effects of the medicine (which may affect more than 1 in 10 people) include feeling drowsy or sleepy and fever.

Future Observations by Authorities

As with any medicine, the MHRA will keep the safety and effectiveness of ganaxolone under close review.
Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.

About MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.?
All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
The MHRA is an executive agency of the Department of Health and Social Care.